Literature DB >> 9533614

Effects of AT1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertensive rats of the stroke prone strain.

J Wagner1, M Drab, J Bohlender, K Amann, W Wienen, D Ganten.   

Abstract

The aim of the study was to assess the effects of chronic angiotensin I receptor blockade on blood pressure, the renin-angiotensin system in plasma and kidney and the extent of renal damage in spontaneously hypertensive rats of the stroke prone strain (SHRsp). Four months old male SHRsp rats were orally treated with a high (10 mg/kg b.w. per day) or a low dose (1 mg/kg b.w. per day) of the AT1 receptor antagonist Telmisartan and compared to Losartan- (20 mg/kg b.w. per day), Captopril-treated (50 mg/kg b.w. per day) or untreated control groups for 38 days. Despite a similar extent of blood pressure reduction in all groups (except low dose Telmisartan), high dose Telmisartan but not Losartan or Captopril significantly reduced left ventricular weight by 24% compared to controls (p<0.05). Renal damage as assessed by urinary albumin or glomerulosclerosis index was significantly reduced in all treatment groups (p<0.02). Plasma renin concentration was significantly elevated (p<0.02) and plasma angiotensinogen significantly lowered (p<0.05) in all pharmacologically treated group compared to controls. In the kidney, renin-mRNA as well as AT1 receptor gene expression were elevated in all treatment groups, but no significant changes were found for renal angiotensinogen-mRNA. Chronic oral treatment of genetically hypertensive rats by the AT1 receptor antagonist Telmisartan reveals a blood pressure lowering and reno-protective effect of this drug comparable to other AT1 receptor antagonists or converting enzyme inhibitors, and demonstrates a marked reduction of cardiac hypertrophy by Telmisartan in this model.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9533614     DOI: 10.3109/10641969809053215

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  7 in total

Review 1.  Telmisartan: a review of its use in the management of hypertension.

Authors:  Anna J Battershill; Lesley J Scott
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 2.  Signaling mechanisms that link salt retention to hypertension: endogenous ouabain, the Na(+) pump, the Na(+)/Ca(2+) exchanger and TRPC proteins.

Authors:  Mordecai P Blaustein; John M Hamlyn
Journal:  Biochim Biophys Acta       Date:  2010-03-06

Review 3.  Telmisartan: a review of its use in hypertension.

Authors:  M Sharpe; B Jarvis; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Long-term effects of telmisartan on blood pressure, the renin-angiotensin-aldosterone system, and lipids in hypertensive patients.

Authors:  Akiko Aoki; Tetsuya Ogawa; Hiroyuki Sumino; Hisao Kumakura; Yoshiaki Takayama; Shuichi Ichikawa; Kosaku Nitta
Journal:  Heart Vessels       Date:  2010-05-29       Impact factor: 2.037

Review 5.  The pump, the exchanger, and endogenous ouabain: signaling mechanisms that link salt retention to hypertension.

Authors:  Mordecai P Blaustein; Jin Zhang; Ling Chen; Hong Song; Hema Raina; Stephen P Kinsey; Michelle Izuka; Takahiro Iwamoto; Michael I Kotlikoff; Jerry B Lingrel; Kenneth D Philipson; W Gil Wier; John M Hamlyn
Journal:  Hypertension       Date:  2008-12-22       Impact factor: 10.190

6.  Angiotensin II receptor blocker telmisartan attenuates aortic stiffening and remodelling in STZ-diabetic rats.

Authors:  Erik Salum; Mark Butlin; Jaak Kals; Mihkel Zilmer; Jaan Eha; Alberto P Avolio; Andres Arend; Marina Aunapuu; Priit Kampus
Journal:  Diabetol Metab Syndr       Date:  2014-05-20       Impact factor: 3.320

7.  Mechanisms Involved in Superiority of Angiotensin Receptor Blockade over ACE Inhibition in Attenuating Neuropathic Pain Induced in Rats.

Authors:  Nora Hegazy; Samar Rezq; Ahmed Fahmy
Journal:  Neurotherapeutics       Date:  2020-07       Impact factor: 6.088

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.